Hypersensitivity to eculizumab, murine proteins or to any of the excipients listed in Description.
SOLIRIS therapy must not be initiated in patients (see Precautions): with unresolved Neisseria meningitidis infection; who are not currently vaccinated against Neisseria meningitidis unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination.